Meeting Banner
Abstract #0949

ADC Decreases in Solid Tumors Following Monotherapy With PEGylated Recombinant Human Hyaluronidase: Results From Early-Phase Clinical Trials

Andres Mauricio Arias-Lorza1 and Natarajan Raghunand1
1Moffitt Cancer Center, Tampa, FL, United States

In early-phase clinical trials, we observed a general decrease in tumor ADC following administration of PEGylated Recombinant Human Hyaluronidase PH20 (PEGPH20) as monotherapy. This decrease was related with reduction of tumor hyaluronan measured in biopsy samples. Reduction in ADC is suggestive of a decrease in tumor water content following hyaluronan depletion by PEGPH20.

This abstract and the presentation materials are available to members only; a login is required.

Join Here